Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 38

Sort by

Sort Order Select

Journal Articles

Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy

Blood (2023) 141 (7): 756–765.

https://doi.org/10.1182/blood.2022017848

Published: 2023

Includes: Supplemental data

Journal Articles

Comprehensive Characterization of Prolonged Unexplained Cytopenias in Relapsed/Refractory Multiple Myeloma Patients Following BCMA-Directed CAR-T Cell Therapy

Blood (2022) 140 (Supplement 1): 614–616.

https://doi.org/10.1182/blood-2022-165646

Published: 2022

Journal Articles

Extramedullary Relapse Post CAR-T

Shambavi Richard, Guido Lancman, Adriana Rossi, Ajai Chari, Samir Parekh, Larysa Sanchez, Cesar Rodriguez, Hearn J. Cho, Joshua Richter, Santiago Thibaud, Kiah Purcell, Elizabeth Aronson, Daniel Verina, Juliet Escalon, Karen Louw, Sundar Jagannath

Blood (2022) 140 (Supplement 1): 4301–4302.

https://doi.org/10.1182/blood-2022-170119

Published: 2022

Journal Articles

Real-World Multiple Myeloma Front-Line Treatment and Outcomes By Transplant in the United States

Joshua Richter, Darren Pan, Taylor Salinardi, Megan S. Rice

Blood (2022) 140 (Supplement 1): 7187–7188.

https://doi.org/10.1182/blood-2022-157812

Published: 2022

Journal Articles

A Phase 1/2, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose-Expansion Study of Single-Agent ISB 1442 in Patients with Relapsed/Refractory Multiple Myeloma

Hanlon Sia, Peter T. Tan, Joshua Richter, Phoebe Joy Ho, Tara Cochrane, Hang Quach, Binod Dhakal, Igor Proscurshim, Tony Jiang, Emaryn Mancino, Yacine Salhi, Sammicheli Stefano, Girish Gudi, Andrew Garton, Eric J. Feldman, Andrew Spencer

Blood (2022) 140 (Supplement 1): 10182–10184.

https://doi.org/10.1182/blood-2022-157585

Published: 2022

Journal Articles

Infections and Severe Hypogammaglobulinemia in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies

Guido Lancman, Kian Parsa, Cesar Rodriguez, Joshua Richter, Hearn J. Cho, Samir Parekh, Shambavi Richard, Adriana Rossi, Larysa Sanchez, Santiago Thibaud, Sundar Jagannath, Ajai Chari

Blood (2022) 140 (Supplement 1): 10073–10074.

https://doi.org/10.1182/blood-2022-163733

Published: 2022

Journal Articles

Gain of chr1q Portends Poor Outcomes in Multiple Myeloma Patients Treated with Venetoclax

Alessandro Lagana, Santiago Thibaud, David T. Melnekoff, Paula Restrepo, Violetta Leshchenko, Jonathan McCafferty, Scott Newman, Abbi Kern, David Corrigan, Feras Hantash, Adriana Rossi, Cesar Rodriguez, Larysa Sanchez, Shambavi Richard, Ajai Chari, Hearn J. Cho, Sundar Jagannath, Joshua Richter, Samir Parekh

Blood (2022) 140 (Supplement 1): 4388–4390.

https://doi.org/10.1182/blood-2022-166572

Published: 2022

Journal Articles

Outcomes with Panobinostat in Heavily Pretreated Multiple Myeloma Patients

Darren Pan, Tarek H. Mouhieddine, Ranjan Upadhyay, Nicole Casasanta, Angela Lee, Nicole Zubizarreta, Erin Moshier, Joshua Richter

Blood (2022) 140 (Supplement 1): 12483–12484.

https://doi.org/10.1182/blood-2022-159806

Published: 2022

Journal Articles

Immune Recovery Post BCMA CAR-T: Implications for Infection Prophylaxis and Vaccinations

Shambavi Richard, Guido Lancman, Santiago Thibaud, Ajai Chari, Samir Parekh, Adriana Rossi, Hearn J. Cho, Larysa Sanchez, Joshua Richter, Cesar Rodriguez, Elizabeth Aronson, Karen Louw, Kiah Purcell, Daniel Verina, Juliet Escalon, Sundar Jagannath

Blood (2022) 140 (Supplement 1): 7444–7446.

https://doi.org/10.1182/blood-2022-170404

Published: 2022

Journal Articles

Timing and Nature of Infections in Multiple Myeloma Patients Treated with Anti-BCMA CAR-T Cells

Guido Lancman, Margaret Shyu, Megan Metzger, Kian Parsa, Hearn J. Cho, Samir Parekh, Joshua Richter, Cesar Rodriguez, Adriana Rossi, Larysa Sanchez, Santiago Thibaud, Sundar Jagannath, Ajai Chari, Shambavi Richard

Blood (2022) 140 (Supplement 1): 7198–7199.

https://doi.org/10.1182/blood-2022-163757

Published: 2022

Journal Articles

Salvage with Sequential T Cell Redirection for Myeloma Patients Who Have Previously Progressed on T Cell Directed Therapy Is Associated with Significant Cellular Activation of the Immune Microenvironment

Adolfo Aleman, Ariel Kogan Zajdman, Yogita Ghodke-Puranik, Bhaskar Upadhyaya, Tarek H. Mouhieddine, Oliver Van Oekelen, Larysa Sanchez, Shambavi Richard, Adriana Rossi, Joshua Richter, Hearn J. Cho, Cesar Rodriguez, Ajai Chari, Sundar Jagannath, Samir Parekh

Blood (2022) 140 (Supplement 1): 4193–4195.

https://doi.org/10.1182/blood-2022-169538

Published: 2022

Journal Articles

Enduring Responses after 1-Year, Fixed-Duration Cevostamab Therapy in Patients with Relapsed/Refractory Multiple Myeloma: Early Experience from a Phase I Study

Blood (2022) 140 (Supplement 1): 4415–4417.

https://doi.org/10.1182/blood-2022-157547

Published: 2022

Journal Articles

Updated Safety and Efficacy of REGN5458, a BCMAxCD3 Bispecific Antibody, Treatment for Relapsed/Refractory Multiple Myeloma: A Phase 1/2 First-in-Human Study

Blood (2022) 140 (Supplement 1): 10140–10141.

https://doi.org/10.1182/blood-2022-159969

Published: 2022

Journal Articles

Impact of COVID-19 on Treatment Patterns and Management of Multiple Myeloma: Insights from the Connect® MM Registry

Joshua Richter, Sikander Ailawadhi, Hans C. Lee, James W. Hardin, Howard R. Terebelo, Rafat Abonour, Lynne I. Wagner, Brian G.M. Durie, James L. Omel, Mohit Narang, Kathleen Toomey, Robert M. Rifkin, Cristina J. Gasparetto, Edward Yu, Jasmeet Anand, Liang Liu, Ying-Ming Jou, Sundar Jagannath

Blood (2022) 140 (Supplement 1): 8089–8091.

https://doi.org/10.1182/blood-2022-158627

Published: 2022

Journal Articles

Initial Results of Dose Escalation of ISB 1342, a Novel CD3xCD38 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)

Blood (2022) 140 (Supplement 1): 7264–7266.

https://doi.org/10.1182/blood-2022-157525

Published: 2022

Journal Articles

Treatment Patterns and Patient Outcomes in Relapsed/Refractory Multiple Myeloma (RRMM) Stratified By Exposure to Lenalidomide or Anti-CD38 Therapy and Double-Class Refractory Status: A Retrospective Electronic Health Record Database Study

Joshua Richter, Peter Feng Wang, Alexa Molinari, Boris Gorsh, Natalie Boytsov, Suzanne Landi, Sue Perera, Prani Paka, Teresa Palumbo, Mei Sheng Duh, Christopher Yee, Anamika Khanal, Sonia Gupta, Ajai Chari

Blood (2022) 140 (Supplement 1): 4338–4340.

https://doi.org/10.1182/blood-2022-164918

Published: 2022

Journal Articles

Subgroup Analysis: Efficacy and Safety of Panobinostat in Combination with SC Bortezomib and Oral Dexamethasone in Multiple Myeloma Patients with Lenalidomide-Refractory Disease

Joshua Richter, Jacob P. Laubach, Steve Stricker, Fredrik H. Schjesvold, David Cohan, Anna Sureda, Ewa Lech-Marańda, Meral Beksac, Vania Hungria, Meletios A. Dimopoulos, Ajai Chari, Paul G. Richardson, Philippe Moreau

Blood (2021) 138 (Supplement 1): 3759.

https://doi.org/10.1182/blood-2021-153694

Published: 2021

Journal Articles

Clinical Outcomes of Relapsed/Refractory Multiple Myeloma Patients Following Treatment with Bispecific Antibodies (BiAbs)

Tarek H. Mouhieddine, Oliver Van Oekelen, Darren Pan, Sarita Agte, Adolfo Aleman, David T. Melnekoff, Guido Lancman, Santiago Thibaud, Larysa Sanchez, Shambavi Richard, Joshua Richter, Hearn Jay Cho, Ajai Chari, Sundar Jagannath, Samir Parekh

Blood (2021) 138 (Supplement 1): 821.

https://doi.org/10.1182/blood-2021-151585

Published: 2021

Journal Articles

Pathogenic Germline Variants in Multiple Myeloma

Santiago Thibaud, Aaron Etra, Ryan Subaran, Zachry Soens, Scott Newman, Rong Chen, Ajai Chari, Hearn Jay Cho, Sundar Jagannath, Deepu Madduri, David T. Melnekoff, Shambavi Richard, Joshua Richter, Larysa Sanchez, Kuan-lin Huang, Alessandro Lagana, Samir Parekh, Kenan Onel

Blood (2021) 138 (Supplement 1): 399.

https://doi.org/10.1182/blood-2021-151495

Published: 2021

Journal Articles

Clinical Outcomes and Treatment Strategies for Relapsed/Refractory Myeloma Patients after Relapse on BCMA-Targeted CAR T

Oliver Van Oekelen, Tarek H. Mouhieddine, Darren Pan, Megan Metzger, Sarita Agte, Adolfo Aleman, David T. Melnekoff, Guido Lancman, Alessandro Lagana, Shambavi Richard, Larysa Sanchez, Joshua Richter, Hearn Jay Cho, Ajai Chari, Sundar Jagannath, Samir Parekh

Blood (2021) 138 (Supplement 1): 2704.

https://doi.org/10.1182/blood-2021-152243

Published: 2021

NARROW

Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy

Comprehensive Characterization of Prolonged Unexplained Cytopenias in Relapsed/Refractory Multiple Myeloma Patients Following BCMA-Directed CAR-T Cell Therapy

Extramedullary Relapse Post CAR-T

Real-World Multiple Myeloma Front-Line Treatment and Outcomes By Transplant in the United States

A Phase 1/2, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose-Expansion Study of Single-Agent ISB 1442 in Patients with Relapsed/Refractory Multiple Myeloma

Infections and Severe Hypogammaglobulinemia in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies

Gain of chr1q Portends Poor Outcomes in Multiple Myeloma Patients Treated with Venetoclax

Outcomes with Panobinostat in Heavily Pretreated Multiple Myeloma Patients

Immune Recovery Post BCMA CAR-T: Implications for Infection Prophylaxis and Vaccinations

Timing and Nature of Infections in Multiple Myeloma Patients Treated with Anti-BCMA CAR-T Cells

Salvage with Sequential T Cell Redirection for Myeloma Patients Who Have Previously Progressed on T Cell Directed Therapy Is Associated with Significant Cellular Activation of the Immune Microenvironment

Enduring Responses after 1-Year, Fixed-Duration Cevostamab Therapy in Patients with Relapsed/Refractory Multiple Myeloma: Early Experience from a Phase I Study

Updated Safety and Efficacy of REGN5458, a BCMAxCD3 Bispecific Antibody, Treatment for Relapsed/Refractory Multiple Myeloma: A Phase 1/2 First-in-Human Study

Impact of COVID-19 on Treatment Patterns and Management of Multiple Myeloma: Insights from the Connect® MM Registry

Initial Results of Dose Escalation of ISB 1342, a Novel CD3xCD38 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)

Treatment Patterns and Patient Outcomes in Relapsed/Refractory Multiple Myeloma (RRMM) Stratified By Exposure to Lenalidomide or Anti-CD38 Therapy and Double-Class Refractory Status: A Retrospective Electronic Health Record Database Study

Subgroup Analysis: Efficacy and Safety of Panobinostat in Combination with SC Bortezomib and Oral Dexamethasone in Multiple Myeloma Patients with Lenalidomide-Refractory Disease

Clinical Outcomes of Relapsed/Refractory Multiple Myeloma Patients Following Treatment with Bispecific Antibodies (BiAbs)

Pathogenic Germline Variants in Multiple Myeloma

Clinical Outcomes and Treatment Strategies for Relapsed/Refractory Myeloma Patients after Relapse on BCMA-Targeted CAR T

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only